Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vivus LLC currently oversees 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The company's prosecution activity is concentrated, featuring 1 distinct examiner and 1 distinct art unit. This structure indicates that the current legal efforts are focused on a specific set of claims or a specific patent application. The absence of multiple active matters suggests a focused or very early stage prosecution phase for the company's current interests.
The busiest examiner for the portfolio is SHOWALTER, ALEXANDER KEITH, who manages 1 busiest examiner pending action. This action accounts for the entirety of the company's pending workload. Consequently, the outcome of the company's current prosecution phase is tied directly to the decisions made by SHOWALTER, ALEXANDER KEITH within the identified art unit. Practitioners should prioritize understanding the specific examination patterns of this examiner, as their feedback will determine the success of the 1 pending office action before the office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRIOS, JENNIFER A | 1 | 37.0% | +49.7% |
| SHOWALTER, ALEXANDER KEITH | 1 | 57.0% | +35.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18440516 | ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT | BERRIOS, JENNIFER A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18440516 | ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT | BERRIOS, JENNIFER A | — |
| 18065437 | METHOD FOR RAPID INFUSION OF CARMUSTINE | SHOWALTER, ALEXANDER KEITH | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18440516 | ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT | BERRIOS, JENNIFER A | 1613 | §102§103§112 | Final Rejection | — | Pending | Feb 13, 2024 |
| 18065437 | METHOD FOR RAPID INFUSION OF CARMUSTINE | SHOWALTER, ALEXANDER KEITH | 1629 | §103DP | Final Rejection | — | Pending | Dec 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVivus LLC has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Jennifer A Berrios has the most, with 1 of Vivus LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.